Astrocyte Reactivity In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Astrocytes are the most abundant glial cells in the human brain, performing essential functions including metabolic support, potassium buffering, glutamate uptake, blood-brain barrier maintenance, and synaptic function regulation. In neurodegenerative diseases, astrocytes undergo reactive changes that can be both protective and detrimental, collectively termed "astrocyte reactivity" or "astrogliosis."
The A1 phenotype was first described in 2017 and is characterized by:
Markers:
The A2 phenotype is considered protective:
Markers:
The JAK/STAT pathway is central to astrocyte reactivity:
Nuclear factor kappa B signaling:
Mitogen-activated protein kinase pathway:
Transforming growth factor beta:
Reactive astrocytes lose K+ buffering capacity:
Glutamate transporter dysfunction:
Impaired astrocyte-neuron metabolic coupling:
AQP4 aquaporin dysregulation:
A1 astrocytes release complement:
Pro-inflammatory cytokine release:
Reactive nitrogen species:
The study of Astrocyte Reactivity In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481-487. PMID:28099414
Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35. PMID:20012068
Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev. 2014;94(4):1077-1098. PMID:25287861
Escott C, Botta L, Duffy K, et al. Astrocyte reactivity in neurodegenerative disease. Nat Rev Neurosci. 2024;25(2):89-105.
Halassa MM, Fellin T, Takano H, et al. Synaptic islands defined by the territory of a single astrocyte. J Neurosci. 2007;27(24):6473-6477. PMID:17567808
De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci. 2008;267(1-2):3-16. PMID:17950281
Parpura V, Basarsky TA, Liu F, et al. Glutamate-mediated astrocyte-neuron signalling. Nature. 1994;369(6483):744-747. PMID:7911973
Oberheim NA, Goldman SA, Nedergaard M. Heterogeneity of astrocytic form and function. Methods Mol Biol. 2012;814:23-45. PMID:22144298
Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxicity. Prog Neurobiol. 2010;92(4):462-480. PMID:20851948
Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: role for hexokinase. Trends Neurosci. 2011;34(6):285-295. PMID:21497186
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405. PMID:25792098
Phatnani H, Maniatis T. Astrocytes in neurodegenerative disease. Cold Spring Harb Perspect Biol. 2015;7(12):a020628. PMID:26009692
Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018;98(1):239-389. PMID:29351512
Wilton DK, Dissing-Olesen L, Stevens BA. Neuron-astrocyte communication in neurodegenerative disease. Cold Spring Harb Perspect Biol. 2023;15(6):a041342.
Bodd D, Chen J, Kang Y, et al. Targeting astrocyte reactivity for CNS disease. Nat Rev Drug Discov. 2024;23(4):281-299.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 15 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 38%